Ziagen(abacavir)
Epzicom, Kivexa, Triumeq, Trizivir, Ziagen (abacavir) is a small molecule pharmaceutical. Abacavir was first approved as Ziagen on 1998-12-17. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Ziagen (generic drugs available since 2012-06-18)
CombinationsTriumeq (generic drugs available since 2012-06-18, discontinued: Epzicom, Trizivir)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Abacavir sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZIAGEN | ViiV Healthcare | N-020978 RX | 1998-12-17 | 1 products, RLD, RS |
Show 1 discontinued
Abacavir sulfate
+
Dolutegravir sodium
+
Lamivudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIUMEQ | ViiV Healthcare | N-205551 RX | 2014-08-22 | 1 products, RLD, RS |
| TRIUMEQ PD | ViiV Healthcare | N-215413 RX | 2022-03-30 | 1 products, RLD, RS |
Abacavir sulfate
+
Lamivudine
Abacavir sulfate
+
Lamivudine
+
Zidovudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIZIVIR | ViiV Healthcare | N-021205 DISCN | 2000-11-14 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| abacavir | ANDA | 2023-08-11 |
| abacavir and lamivudine | ANDA | 2023-10-30 |
| abacavir sulfate | ANDA | 2022-06-14 |
| abacavir sulfate, lamivudine and zidovudine | ANDA | 2016-05-04 |
| abacavir, lamivudine and zidovudine | ANDA | 2023-10-31 |
| epzicom | New Drug Application | 2022-12-14 |
| triumeq | New Drug Application | 2021-03-23 |
| triumeq triumeq pd | New Drug Application | 2023-06-15 |
| trizivir | New Drug Application | 2021-02-17 |
| ziagen | New Drug Application | 2023-09-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
| hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ, VIIV HLTHCARE | |||
| 2026-12-15 | PED | ||
| 2026-06-15 | M-294 | ||
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ PD, VIIV HLTHCARE | |||
| 2026-12-15 | PED | ||
| 2026-06-15 | NPP | ||
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF06: Abacavir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR02: Lamivudine and abacavir
— J05AR04: Zidovudine, lamivudine and abacavir
— J05AR13: Lamivudine, abacavir and dolutegravir
HCPCS
No data
Clinical
Clinical Trials
261 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 19 | 37 | 58 | 38 | 28 | 175 |
| Hiv | D006678 | — | O98.7 | 4 | 5 | 7 | 18 | 3 | 35 |
| Infections | D007239 | EFO_0000544 | — | 4 | 4 | 12 | 3 | 6 | 29 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | — | 3 | 3 | 7 |
| Lipodystrophy | D008060 | HP_0009125 | E88.1 | — | 2 | — | 3 | 1 | 6 |
| Hiv-1 | D015497 | — | — | — | 1 | 1 | 2 | — | 4 |
| Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | — | — | — | — | 4 | — | 4 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | 1 | 2 | — | 3 |
| Body weight changes | D001836 | — | — | — | — | — | 2 | — | 2 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | 3 | — | — | 4 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | 1 | — | 1 | 2 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | 1 | 1 | — | — | 2 |
| Glycogen storage disease type ii | D006009 | Orphanet_365 | E74.02 | — | — | 1 | — | — | 1 |
| Malaria | D008288 | EFO_0001068 | B54 | — | — | 1 | — | — | 1 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | — | 1 | — | — | 1 |
| Lactic acidosis | D000140 | HP_0003128 | E87.20 | — | 1 | 1 | — | — | 1 |
| Aids dementia complex | D015526 | EFO_0002608 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Htlv-ii infections | D015491 | EFO_1001349 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Hiv seronegativity | D018023 | — | — | 1 | — | — | — | — | 1 |
| Hepatitis c | D006526 | — | B19.2 | 1 | — | — | — | — | 1 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
| Wasting syndrome | D019282 | — | — | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | — | 1 | 1 |
| Hepatitis b | D006509 | — | — | — | — | — | — | 1 | 1 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | — | — | 1 | 1 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | — | — | 1 | 1 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Abacavir |
| INN | abacavir |
| Description | Abacavir is a 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor, an antiviral drug and a drug allergen. |
| Classification | Small molecule |
| Drug class | antivirals: carbocyclic nucleosides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1 |
Identifiers
| PDB | — |
| CAS-ID | 136470-78-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1380 |
| ChEBI ID | 421707 |
| PubChem CID | 441300 |
| DrugBank | DB01048 |
| UNII ID | WR2TIP26VS (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Abacavir
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Abacavir
+
Lamivudine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Abacavir
+
Lamivudine
+
Zidovudine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,784 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abacavir, Abacavir and lamivudine, Abacavir sulfate, Abacavir sulfate, lamivudine and zidovudine, Abacavir, lamivudine and zidovudine, Epzicom, Triumeq, Triumeq triumeq pd, Trizivir, Ziagen
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17,965 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use